Allergan said yesterday its fourth-quarter earnings rose 6.4 per cent, as higher sales of its eye drugs Lumigan and Restasis offset lower-than-expected sales of wrinkle treatment Botox. The company's forecast for the year was lower than anticipated, sending its shares down 1.8 per cent in mid-morning trading, although some analysts consider the outlook to be conservative. Net income rose to $279.8m (£176.8m), or 90 cents a share, from $263m, or 85 cents a share, a year ago. Product sales rose 7.2 per cent to $1.38bn. Revenue rose to $1.4bn from $1.3bn.
Botox maker’s earnings rise
Friday 3rd February 2012, 2:28am
Latest Jobs:
-
Provide superior service and underwriting expertise to support profitable growth and development of the business.Underwriting, servicing and negotiating complex risk throughout the annual cycleBuilding and maintaining business relationshipsWorking at all times in accordance with agreed
-
To achieve regional income and profit objectives by managing the technical performance of the branch account and by delivering an efficient case underwriting service to brokers. Collaborate with the Executive Manager to develop the branch
-
This FTSE listed retail business is a household name within the UK. Having enjoyed continual growth throughout the economic downtown, they are now looking to recruit an individual to drive [profitability through their insurance product
-
Michael Page Insurance are currently looking for sales professionals, with a proven track record of success against targets, to transfer their experience and skills to the role of a recruitment consultant. You may not have
Editor's Letter
Allister Heath
Government’s job is to shield UK taxpayers from Euro chaos
WHEN a country’s president warns that its banks are in danger, and reveals that depositors are pulling...
